| 7.21 -0.46 (-6%) | 07-02 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.44 | 1-year : | 9.78 |
| Resists | First : | 6.37 | Second : | 8.38 |
| Pivot price | 4.42 |
|||
| Supports | First : | 3.11 | Second : | 2.59 |
| MAs | MA(5) : | 3.9 |
MA(20) : | 4.88 |
| MA(100) : | 4.84  |
MA(250) : | 4.36 |
|
| MACD | MACD : | -0.7 |
Signal : | -0.6 |
| %K %D | K(14,3) : | 23 |
D(3) : | 20.6 |
| RSI | RSI(14): 32.5 |
|||
| 52-week | High : | 8.38 | Low : | 2.35 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ LIXT ] has closed above bottom band by 10.8%. Bollinger Bands are 13.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.05 - 4.07 | 4.07 - 4.09 |
| Low: | 3.56 - 3.58 | 3.58 - 3.59 |
| Close: | 3.95 - 3.98 | 3.98 - 4.01 |
Lixte Biotechnology Holdings, Inc. is a drug discovery company focused on developing new treatments. It employs biomarker technology to identify crucial enzyme targets associated with serious, widespread diseases, then designs innovative compounds to act upon these targets. The company's primary focus lies in protein phosphatase inhibitors, which are being investigated for use both independently and in combination with cytotoxic agents, radiation therapy, and immune checkpoint blockers. Its pipeline includes two main categories of compounds, currently in various stages of pre-clinical and clinical development. The LB-100 series consists of novel chemical entities aimed at treating various cancers, vascular diseases, and metabolic disorders. Meanwhile, the LB-200 series is being developed to address chronic hereditary conditions, such as Gaucher's disease, as well as specific cancers and neurodegenerative ailments. Lixte Biotechnology Holdings, Inc. has forged significant alliances, including a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc. Additionally, it has collaboration agreements for investigator-initiated clinical trials with the Spanish Sarcoma Group, the Netherlands Cancer Institute, and the Oncode Institute. Founded in 2005, the company is headquartered in Pasadena, California.
Fri, 31 Jul 2026
Vanguard Capital Management (LIXT) discloses 5.02% ownership in Lixte - Stock Titan
Thu, 02 Jul 2026
Lixte Biotechnology Completes Merger With NOMAD; Issues 50.4K Series D Preferred and 3.0M Shares - TradingView
Fri, 26 Jun 2026
LIXTE Biotechnology Holdings, Inc. Added to Russell Microcap Index - Quiver Quantitative
Thu, 18 Jun 2026
LIXTE loans NOMAD $6.5M before power-storage deal closes - Stock Titan
Thu, 18 Jun 2026
LIXTE Biotechnology Provides Update on NOMAD Acquisition; Transaction Expected to Close On or About July 1, 2026 - Yahoo Finance
Tue, 16 Jun 2026
Lixte Biotechnology to Acquire Nomad Transportable Power Systems in Stock Deal of Up to 53.5M Shares - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 17 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 7.2 (%) |
| Held by Institutions | 4.8 (%) |
| Shares Short | 386 (K) |
| Shares Short P.Month | 70 (K) |
| EPS | -1.14 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.68 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -3.16 |
| PEG Ratio | 0 |
| Price to Book value | 5.29 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|